Obesity: Dietary Factors, Assessment, and Evidence-Based Interventions

This is a broad topic spanning etiology, clinical assessment, and multiple tiers of management. Here's the map of what it covers, pulled from the medical library (Harrison's Principles of Internal Medicine 22e, Schwartz's Principles of Surgery, Comprehensive Clinical Nephrology, Textbook of Family Medicine, Miller's Anesthesia, and others):

1. Dietary and Lifestyle Etiology

Energy imbalance: caloric surplus, energy density of foods, ultra-processed food intake
Macronutrient patterns: added sugars/sugar-sweetened beverages, dietary fat quality, fiber intake
Behavioral drivers: portion size, meal frequency/timing, sedentary behavior, sleep, socioeconomic and environmental "obesogenic" factors

2. Clinical Assessment

Anthropometrics: BMI classification, waist circumference, waist-to-hip ratio
Body composition: bioimpedance, DEXA, visceral vs. subcutaneous fat distinction (visceral fat drives IL-6/TNF-alpha/CRP-mediated inflammation and cardiometabolic risk)
History/exam: onset, weight trajectory, secondary causes (hypothyroidism, Cushing's, medications), comorbidity screening (T2DM, hypertension, OSA, NAFLD, PCOS, osteoarthritis)
Risk stratification tools used before treatment planning (including bariatric surgery candidacy criteria)

3. Lifestyle/Dietary Interventions

Structured caloric-deficit diets (low-calorie, very-low-calorie, Mediterranean, low-carbohydrate, intermittent fasting)
Behavioral therapy, physical activity prescription, combined multicomponent programs

4. Pharmacotherapy

GLP-1/GIP receptor agonists (semaglutide, tirzepatide), orlistat, phentermine-topiramate, naltrexone-bupropion
2025 clinical guideline updates (see evidence note below)

5. Surgical/Bariatric Management

Mechanisms of weight loss surgery, procedure types (sleeve gastrectomy, Roux-en-Y, adjustable band), outcomes, and perioperative considerations (notably covered in anesthesia and surgery texts)

6. Special Populations

Pediatric/adolescent obesity, obesity in CKD/renal disease, obesity and cardiovascular/rheumatologic disease interactions

Evidence update flag: Two recent systematic reviews are relevant and may refine textbook content:

A 2025 CMAJ clinical practice guideline update on pharmacotherapy for adult obesity management (PMID 40789597) - reflects newer anti-obesity agent recommendations that predate most textbook editions.
A 2025 meta-analysis on diet therapy for pediatric/adolescent obesity (PMID 40167375), synthesizing RCT evidence on lifestyle diet interventions in children.

I haven't gone deep on any single area yet since this topic is too large to cover fully in one response. Which part would you like me to focus on in detail?

Asking for Preferences

Which part of obesity would you like a detailed, in-depth answer on?

This is a shared conversation. Sign in to Orris to start your own chat.